The global FMS-Like Tyrosine kinase 3 (FLT3) inhibitors market size was USD 405.6 Million in 2021 and is expected to register a revenue CAGR of 14.6% during the forecast period, according to the latest analysis by Emergen Research. Rising high-value investments for Research and Development (R&D) initiatives by various major pharmaceutical companies for improvement in therapy tolerability and drugs is a key factor driving market revenue growth. In addition, rising incidences of Acute Myeloid Leukemia (AML) and relapse cases, a growing number of potential pipeline drugs, and increasing approvals of new FLT3 inhibitor drugs by regulatory bodies are driving the revenue growth of the FLT3 inhibitors market.
The comprehensive and significant market research study on FMS Like Tyrosine kinase 3 inhibitors offers business strategies, qualitative and quantitative analyses, and emerging trends. The report provides an in-depth examination and analysis of the key elements of the global FMS Like Tyrosine kinase 3 inhibitors market. By conducting extensive primary and secondary research and analyzing the drivers, constraints, challenges, trends, and opportunities of the FMS Like Tyrosine kinase 3 inhibitors market, the research analysts created this report.
According to Novartis, AML accounts for approximately 25% of all adult leukemia and has lowest survival rate. FDA has now authorized three FLT3 inhibitors for use in the U.S. Midostaurin is approved for first-line treatment with chemotherapy, but gilteritinib is approved for R/R disease. Quizartinib and crenolanib are two new AML inhibitors in late-stage development for first-line and R/R treatments. Various advantages of improved targeted medicines, such as increased long-term survival rates, quality, and safety, are driving the growth of the FLT3 inhibitors market. According to Cancer.net, the 5-year survival rate for individuals aged 20 years and older with AML is 27%, whereas it is 69% for individuals younger than 20. In addition, the prognosis and survival of AML patients are strongly dependent on their mutation profile and age. Lower survival rates are due to the aging patient population’s unfavorable mutation profile mixed with their inability to tolerate intense therapy.
Global FMS Like Tyrosine kinase 3 Inhibitors Market Highlights:
- Regional demand estimation and forecast
- Product Mix Matrix
- R&D Analysis
- Cost-Benefit Analysis
- Pre-commodity pricing volatility
- Supply chain optimization analysis
- Technological updates analysis
- Raw Material Sourcing Strategy
- Competitive Analysis
- Mergers & Acquisitions
- Location Quotients Analysis
- Carbon Footprint Analysis
- Patent Analysis
- Vendor Management
Competitive Landscape:
The latest study provides an insightful analysis of the broad competitive landscape of the global FMS Like Tyrosine kinase 3 Inhibitors market, emphasizing the key market rivals and their company profiles. A wide array of strategic initiatives, such as new business deals, mergers & acquisitions, collaborations, joint ventures, technological upgradation, and recent product launches, undertaken by these companies has been discussed in the report. The report analyzes various elements of the market’s competitive scenario, such as the regulatory standards and policies implemented across the industry over recent years. Our team of experts has leveraged several powerful analytical tools, such as Porter’s Five Forces analysis and SWOT analysis, to deliver a comprehensive overview of the global FMS Like Tyrosine kinase 3 Inhibitors market and pinpoint the fundamental growth trends.
Key Companies Profiled in the Report are:
Astellas Pharma Inc., Novartis AG, Pfizer Inc., Daiichi Sanyo Company, Limited, Cullinan Oncology, Inc., AROG Pharmaceuticals, Inc., Aptose Biosciences Inc., FUJIFILM Pharmaceuticals U.S.A., Inc., CSPC Pharmaceutical Group Limited, and Allarity Therapeutics, Inc
Key Parameters Analyzed in This Section:
- Company Profiles
- Gross Revenue
- Profit margins
- Product sales trends
- Product pricing
- Industry Analysis
- Sales & distribution channels
Regional Segmentation:
- North America
- Latin America
- Europe
- Middle East & Africa
- Asia Pacific
Key Points Covered in This Section:
- Regional contribution
- Estimated revenue generation
- Vital data and information about the consumption rate in all the leading regional segments
- An expected rise in market share
- Forecast growth in the overall consumption rate
Click to access the Report Study, Read key highlights of the Report and Look at Projected Trends @ https://www.emergenresearch.com/industry-report/fms-like-tyrosine-kinase-3-inhibitors-market
Some Key Highlights From the Report
- The gilteritinib segment accounted for largest revenue share in 2021 owing to continuing clinical trials and increasing regulatory approvals. Gilteritinib, which is a kinase inhibitor, is recommended for people with acute myeloid leukemia that has relapsed or become resistant to treatment and has FLT3-TKD or FLT3-ITD mutation. This can increase patients survival rates, which is one of the main requirements for getting regulatory approval. For patients with severe, relapsing, or refractory illness, gilteritinib is a safe, mutation-targeted therapeutic option. A complex pyrazine carboxamide derivative, medication also has increased activity, selectivity, and effectiveness against FLT3-TKD and FLT3-ITD mutations.
- Type 1 FLT3 inhibitors segment accounted for largest revenue share in 2021 owing to increasing number of successful clinical trials and research studies. Type 1 inhibitors are more effective in AML cells containing either ITD or TKD mutations as they inhibit ATP binding in contrast to Type 2 FLT3 inhibitors. Moreover, Type 1 FLT3 inhibitors can be used in patients who have relapsed owing to acquired TKD mutations, which is one of the key factors driving revenue growth of the market. Type 1 inhibitors include midostaurin, crenolanib, and gilteritinib. Additionally, better efficacy, fewer side effects, and low toxicity of drugs are major factors driving revenue growth of this segment.
- The North America market accounted for largest revenue share in 2021. A few factors driving market revenue growth include surging number of AML patients, rising requirement for targeted therapies as well as increasing investments by major pharmaceutical companies for R&D in the area of FLT3 inhibitors drug development. Furthermore, rising collaborations between governments and pharmaceutical companies and increasing number of approval of new innovative drugs along with a number of potential pipeline drugs are significantly contributing to growth of the FLT3 inhibitors market in North America.
Market Overview:
The report bifurcates the FMS Like Tyrosine kinase 3 Inhibitors market on the basis of different product types, applications, end-user industries, and key regions of the world where the market has already established its presence. The report accurately offers insights into the supply-demand ratio and production and consumption volume of each segment.
Segments Covered in this report are:
- Drug Type Outlook (Revenue, USD Million; 2019-2030)
- Midostaurin
- Gilteritinib
- Sorafenib
- Therapies Outlook (Revenue, USD Million; 2019-2030)
- Type 1 FLT3 inhibitors
- Type 2 FLT3 inhibitors
- Regional Outlook (Revenue, USD Million; 2019–2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Benelux
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Turkey
- Rest of Middle East & Africa
- North America
Additional information offered by the report:
- Along with a complete overview of the global Cobots market, the report provides detailed scrutiny of the diverse market trends observed on both regional and global levels.
- The report elaborates on the global Cobots market size and share governed by the major geographies.
- It performs a precise market growth forecast analysis, cost analysis, and a study of the micro- and macro-economic indicators.
- It further presents a detailed description of the company profiles of the key market contenders.
Thank you for reading our report. If you have any requests for customization of the latest report, kindly get in touch with us. Our team will assist you and ensure the report is designed as per your requirements.
About Us:
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
